Last reviewed · How we verify
Gestovis (pentagestrone acetate)
Gestovis (generic name: pentagestrone acetate) is a pentagestrone acetate drug. It is currently in unknown development.
Pentagestrone acetate is a progestin that works by binding to progesterone receptors in the body, mimicking the effects of the natural hormone progesterone.
Gestovis, also known as pentagestrone acetate, is a small molecule drug in the pentagestrone acetate class. Unfortunately, there is limited information available on this compound. It is not clear what specific condition or disease it is intended to treat. Gestovis is not currently listed as an approved medication by the FDA, and its commercial status is unknown. Further research is needed to determine its safety and efficacy.
At a glance
| Generic name | pentagestrone acetate |
|---|---|
| Drug class | pentagestrone acetate |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body has locks on cells that only open with a special key. Progesterone is that key, and pentagestrone acetate is a copy of the key that can fit into those locks and unlock the cells, allowing them to function properly.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gestovis CI brief — competitive landscape report
- Gestovis updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Gestovis
What is Gestovis?
How does Gestovis work?
What is the generic name of Gestovis?
What drug class is Gestovis in?
What development phase is Gestovis in?
Related
- Drug class: All pentagestrone acetate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing